Lead Product(s) : CAM-101
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Aventacell Biomedical
Deal Size : $3.0 million
Deal Type : Financing
Cambium Bio Successfully Closes A$3.0M Financing Round
Details : The proceeds will primarily support the advancement of CAM-101 Elate Ocular through its registration-enabling Phase 3 clinical trials for dry eye disease.
Product Name : CAM-101
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 12, 2024
Lead Product(s) : CAM-101
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Aventacell Biomedical
Deal Size : $3.0 million
Deal Type : Financing
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PolyActiva Announces Positive Phase IIa Results for PA5108 Ocular Implant
Details : PA5108 Ocular Implant with Prezia™ technology are being developed to offer a safe and effective, fully biodegradable therapy, which is investigated for the treatment of Open-Angle Glaucoma .
Product Name : PA5108
Product Type : HPAPI
Upfront Cash : Inapplicable
February 17, 2022
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sozinibercept,Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : $150.0 million
Deal Type : Public Offering
Opthea Files for a $150 Million US IPO
Details : Opthea is working on a new drug that targets other VEGF proteins from those approved, including Bayer/Regeneron’s Eylea as well as Lucentis, namely VEGF-C and VEGF-D, for use in combination with VEGF-A drugs.
Product Name : OPT-302
Product Type : Protein
Upfront Cash : Undisclosed
September 25, 2020
Lead Product(s) : Sozinibercept,Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : $150.0 million
Deal Type : Public Offering
Lead Product(s) : Sozinibercept,Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The outcome of the meetings supports the progression of OPT-302 into Phase 3 and pre-commercial development. The company is on-track to initiate Phase 3 trials in early 2021.
Product Name : OPT-302
Product Type : Protein
Upfront Cash : Inapplicable
August 21, 2020
Lead Product(s) : Sozinibercept,Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable